Nintedanib Stada (Nintedanib)

Nintedanib blocks multiple receptor tyrosine kinases—VEGFR, PDGFR and FGFR—thereby inhibiting fibroblast proliferation, new blood‑vessel formation, and extracellular matrix deposition. This multi‑targeted inhibition reduces fibrotic tissue remodeling in the lungs and limits tumor‑associated vascular growth when used with chemotherapy.

The specific dose and dosing schedule are determined by the prescribing clinician based on the patient’s condition, weight, liver function and concomitant therapies. Healthcare professionals follow approved labeling and clinical guidelines to individualise therapy for each indication.

Safety data for Nintedanib in pregnancy and lactation are limited, and the product is classified as contraindicated or not recommended for use in these populations. Women of child‑bearing potential should use effective contraception, and breastfeeding mothers should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

The primary alternative for idiopathic pulmonary fibrosis is pirfenidone, another antifibrotic agent with a different mechanism focused on cytokine modulation. Nintedanib’s multi‑kinase inhibition offers broader activity against angiogenic and fibrotic pathways, which can be advantageous in certain patients, while pirfenidone may have a more favorable gastrointestinal profile for some individuals.

Store Nintedanib Stada at room temperature, below 25 °C, in the original blister pack or container. Protect the tablets from moisture, excessive heat and direct sunlight to maintain potency throughout the shelf life.

Nintedanib Stada is taken orally, usually as a whole tablet swallowed with a glass of water. It can be taken with or without food, but patients should follow the prescriber’s instructions regarding timing relative to meals to optimise absorption and minimize gastrointestinal discomfort.

Clinicians and patients should be vigilant for signs of liver injury (elevated transaminases, jaundice), severe bleeding events, cardiovascular complications such as myocardial infarction, and rare but serious gastrointestinal perforations. Prompt medical evaluation is essential if any of these symptoms arise.

Nintedanib is contraindicated in patients with severe hepatic impairment (Child‑Pugh C), those with known hypersensitivity to the active ingredient or any excipients, and individuals receiving strong CYP3A4 inhibitors that cannot be discontinued. Caution is also advised for patients with uncontrolled cardiovascular disease or active bleeding disorders.